![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RB Rothman, A Reid, A Mahboubi, CH Kim, BR De Costa, AE Jacobson and KC Rice
Unit on Receptor Studies, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892.
Equilibrium binding studies with the sigma receptor ligand [3H]1,3-di(2- tolyl)guanidine ([3H]DTG) demonstrated two high affinity binding sites in membranes prepared from guinea pig brain. The apparent Kd values of DTG for sites 1 and 2 were 11.9 and 37.6 nM, respectively. The corresponding Bmax values were 1045 and 1423 fmol/mg of protein. Site 1 had high affinity for (+)-pentazocine, haloperidol, (R)-(+)-PPP, carbepentane, and other sigma ligands, suggesting a similarity with the dextromethorphan/sigma 1 binding site described by Musacchio et al. [Life Sci. 45:1721-1732 (1989)]. Site 2 had high affinity for DTG and haloperidol (Ki = 36.1 nM) and low affinity for most other sigma ligands. Kinetic experiments demonstrated that [3H]DTG dissociated in a biphasic manner from both site 1 and site 2. DTG and haloperidol increased the dissociation rate of [3H]DTG from site 1 and site 2, demonstrating the presence of pseudoallosteric interactions. Inorganic calcium channel blockers such as Cd2+ selectively increased the dissociation rate of [3H]DTG from site 2, suggesting an association of this binding site with calcium channels.
This article has been cited by other articles:
|
|
 |
|
  J. J. Pariser, J. S. Partilla, C. M. Dersch, S. Ananthan, and R. B. Rothman Studies of the Biogenic Amine Transporters. 12. Identification of Novel Partial Inhibitors of Amphetamine-Induced Dopamine Release J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 286 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Rothman, D. L. Murphy, H. Xu, J. A. Godin, C. M. Dersch, J. S. Partilla, K. Tidgewell, M. Schmidt, and T. E. Prisinzano Salvinorin A: Allosteric Interactions at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 801 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Partilla, A. G. Dempsey, A. S. Nagpal, B. E. Blough, M. H. Baumann, and R. B. Rothman Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 237 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Nightingale, C. M. Dersch, T. L. Boos, E. Greiner, W. J. Calhoun, A. E. Jacobson, K. C. Rice, and R. B. Rothman Studies of the Biogenic Amine Transporters. XI. Identification of a 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) Analog That Allosterically Modulates the Serotonin Transporter J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 906 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Pechnick and R. E. Poland Comparison of the Effects of Dextromethorphan, Dextrorphan, and Levorphanol on the Hypothalamo-Pituitary-Adrenal Axis J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Soriani, H. Vaudry, Y. A. Mei, F. Roman, and L. Cazin Sigma Ligands Stimulate the Electrical Activity of Frog Pituitary Melanotrope Cells through a G-Protein-Dependent Inhibition of Potassium Conductances J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 163 - 171. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. Jbilo, H. Vidal, R. Paul, N. De Nys, M. Bensaid, S. Silve, P. Carayon, D. Davi, S. Galiegue, B. Bourrie, et al. Purification and Characterization of the Human SR 31747A-binding Protein. A NUCLEAR MEMBRANE PROTEIN RELATED TO YEAST STEROL ISOMERASE J. Biol. Chem., October 24, 1997; 272(43): 27107 - 27115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Whittemore, V. I. Ilyin, and R. M. Woodward Antagonism of N-Methyl-D-Aspartate Receptors by sigma Site Ligands: Potency, Subtype-Selectivity and Mechanisms of Inhibition J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 326 - 338. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
